Denied Botulinum Toxin Appeals: Reviewer Outcomes

Therapeutic injection of a botulinum toxin product for a neurological or muscular indication, billed under the product's supply code with a separate injection code. Chronic migraine, spasticity, cervical dystonia and overactive bladder are the common medical-benefit indications.

What the independent reviewers decided

68%

overturned by the independent reviewer

117

of 171 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny botulinum toxin injection

The policy's definition of chronic — headache days per month, duration in months — is not evidenced in the record.
A required trial of preventive or oral agents is not documented.
The indication is not one the FDA labelling covers and the policy limits coverage to labelled uses.
Continuation is denied because the response to the previous cycle is not documented against a baseline.

What actually carried the cases that won

Chronicity carried these decisions, with FDA labelling as one of the two authorities reviewers relied on most — an unusual pairing that tells you what the appeal has to do. The record needs to meet the policy's own definition of chronic in its own units, and to locate the request inside a labelled indication where one exists. Records that described the condition as long-standing without the counts the policy specifies were the ones that did not survive.

What the record showed	Share of overturned decisions
The condition was documented as chronic or long-standing	69%
Prior treatment was documented	64%
Conservative treatment was documented as failed	56%
A published guideline supported the request	35%
The functional impact on the patient was documented	32%
The diagnosis was confirmed	23%
The severity or urgency was documented	15%
Objective findings were documented	4%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 50% of the overturned decisions
FDA labeling — in 34% of the overturned decisions
Clinical guidelines — in 19% of the overturned decisions
Specialty-society criteria — in 15% of the overturned decisions
Standard of care — in 4% of the overturned decisions

botulinum toxin injection denials — frequently asked

Is a denied botulinum toxin claim worth appealing?

68% of 171 California independent medical reviews were overturned — better than two in three, and consistent with denials that turn on documentation thresholds rather than on the treatment's validity.

How should chronicity be documented?

In the policy's units. If the policy defines chronic migraine by headache days per month over a stated period, the record should carry that count from a diary or the chart — not a narrative that the headaches have been going on for years.

Does continuation get treated differently from initiation?

Yes. Continuation denials generally turn on whether the previous cycle's response is documented against a baseline. A recorded reduction — in days, in dose, in a functional measure — is what those appeals rest on.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →